Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by action- Fine €4.75bn 96 % · 1 case
- Other €217.1m 4 % · 4 cases
Who?
by companyWhen?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q3 2023 | 0 | — |
| Q4 2023 | 0 | — |
| Q1 2024 | 0 | — |
| Q2 2024 | 0 | — |
| Q3 2024 | 0 | — |
| Q4 2024 | 0 | — |
| Q1 2025 | 0 | — |
| Q2 2025 | 1 | €177.8m |
| Q3 2025 | 0 | — |
| Q4 2025 | 0 | — |
| Q1 2026 | 0 | — |
| Q2 2026 | 2 | €4.76bn |
| Q3 2026 | 2 | €27.5m |
5 cases
10 Sep 2026 Dompé U.S. Inc.Dompé U.S.: 32 million USD – Medicare patients’ co-payments covered via foundations €27.5m
From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.
Benefits flowing to customers via foundations or other third parties remain benefits provided by the company – donations to patient assistance programmes require strict independence.
Benefits to patients and customers via third parties
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- Self-disclosure.
Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.
- HHS-OIG Enforcement Actions: Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks (10.09.2026) Enforcement database of an authority
- U.S. Department of Justice: Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks (10.09.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
10 Aug 2026 Veloxis Pharmaceuticals Inc.Veloxis: over 46 million USD – luxury trips, dinners and gifts for transplant teams Other
From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.
Invitations and gifts to decision-makers must not only be limited but also fully reported to transparency registers.
Gifts, travel and hospitality for healthcare professionals; transparency reporting
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- DOJ: Veloxis Pharmaceuticals Agrees to Pay Over $46M to Resolve Criminal and Civil Liability for Kickback Schemes (10.08.2026) Press release of an authority
- HHS-OIG Enforcement Actions: Veloxis Pharmaceuticals Agrees to Pay Over $46M … (10.08.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
14 May 2026 Takeda Pharmaceuticals U.S.A., Inc.Takeda: 13.7 million USD – speaker fees and luxury meals for prescribing physicians €11.7m
From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.
Speaker programmes need a demonstrable educational purpose – repeated attendance and expensive hospitality turn them into inducements.
Invitations, hospitality and fees for healthcare professionals
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.
- DOJ: Takeda Agrees to Pay $13.6M to Resolve False Claims Allegations Relating to Improper Payments (14.05.2026) Press release of an authority
- HHS-OIG Enforcement Actions: Takeda Agrees to Pay $13.6M … Improper Payments to Physicians (14.05.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
28 Apr 2026 Purdue Pharma L.P.Purdue Pharma: 5.544 billion USD penalty – including kickbacks via the speaker programme €4.75bn
Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.
Fee programmes for customers who drive revenue can become part of a criminal overall scheme – with consequences that threaten the company’s existence.
Speaker fees and benefits for prescribing physicians
- Authority / court
- U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Culpability
- intentional
Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.
- HHS-OIG Enforcement Actions: Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies (28.04.2026) Enforcement database of an authority
- U.S. Department of Justice: Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies (28.04.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
28 Apr 2025 Gilead Sciences, Inc.Gilead: 202 million USD – speaker programmes with fees, luxury meals and travel €177.8m
Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.
Selecting speakers by prescription volume turns continuing education into bribery – selection criteria and hospitality limits must be documented.
Fees and hospitality at professional events
- Authority / court
- U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 29 Apr 2025
Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.
- HHS-OIG Enforcement Actions: U.S. Attorney Announces $202 Million Settlement With Gilead Sciences … Speaker Programs (29.04.2025) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link